Trade Soligenix, Inc. - SNGX CFD

Add to favourite

2.131

0.47%

View detailed chart

To be able to trade stocks like this, create an account and apply for a stock listing.

Create Account

Summary
Historical Data

Trading сonditions

Spread

0.118

Long position overnight fee

-0.023679%

Short position overnight fee

0.001457%

Overnight fee time

21:00 (UTC)

Min traded quantity

0.001

Currency

USD

Margin

5.00%

Stock exchange

United States of America

Commission on trade

Key Stats

Prev. Close	2.121
Open	2.121
1-Year Change	258.28%
Day's Range	2.121 - 2.151

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Apr 1, 2025	2.131	0.010	0.47%	2.121	2.191	2.121
Mar 31, 2025	2.121	0.000	0.00%	2.121	2.161	2.091
Mar 28, 2025	2.141	-0.060	-2.73%	2.201	2.241	2.021
Mar 27, 2025	2.191	-0.070	-3.10%	2.261	2.261	2.051
Mar 26, 2025	2.281	-0.030	-1.30%	2.311	2.341	2.221
Mar 25, 2025	2.291	0.020	0.88%	2.271	2.341	2.231
Mar 24, 2025	2.251	-0.020	-0.88%	2.271	2.291	2.251
Mar 21, 2025	2.271	0.070	3.18%	2.201	2.341	2.201
Mar 20, 2025	2.291	0.050	2.23%	2.241	2.331	2.241
Mar 19, 2025	2.311	0.000	0.00%	2.311	2.311	2.291
Mar 18, 2025	2.261	0.000	0.00%	2.261	2.301	2.221
Mar 17, 2025	2.291	0.010	0.44%	2.281	2.331	2.271
Mar 14, 2025	2.251	0.040	1.81%	2.211	2.281	2.211
Mar 13, 2025	2.241	0.010	0.45%	2.231	2.261	2.231
Mar 12, 2025	2.231	0.040	1.83%	2.191	2.291	2.191
Mar 11, 2025	2.191	0.030	1.39%	2.161	2.231	2.161
Mar 10, 2025	2.221	-0.080	-3.48%	2.301	2.361	2.201
Mar 7, 2025	2.311	0.030	1.32%	2.281	2.331	2.241
Mar 6, 2025	2.191	0.020	0.92%	2.171	2.291	2.171
Mar 5, 2025	2.171	0.000	0.00%	2.171	2.201	2.171

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

1:1
2:1
3:1
5:1
10:1
20:1

Leverage

20:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Soligenix, Inc. Company profile

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301, a novel photodynamic therapy, which has completed Phase 3 clinical trial to treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase 3 clinical trial to treat oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate, which is in Phase 1/2 clinical trial for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including pediatric Crohn''s disease and acute radiation enteritis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase 1a and 1b clinical trials; SGX943, a melioidosis therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; and ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.

Industry:

Bio Therapeutic Drugs

Suite C-10
29 Emmons Drive
PRINCETON
NEW JERSEY 08540
US